Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Journal of Intensive Care Year : 2021

Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study

Abstract

Dexamethasone improves survival of patients with COVID-19 acute respiratory distress syndrome, but might shorten the delay between the start of invasive mechanical ventilation and the occurrence of ventilator-associated pneumonia, suggesting possible worsening of COVID-19-induced immune dysfunction with this treatment. In a prospective observational study, we found that mechanically ventilated patients with COVID-19 treated with dexamethasone presented earlier ventilator-associated pneumonia, had significantly lower monocyte Human Leukocyte Antigen-DR expression and number of circulating CD4 + cells after ICU admission, than those not treated with corticoids.
Fichier principal
Vignette du fichier
s40560-021-00580-6.pdf (874.87 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03753365 , version 1 (18-08-2022)

Identifiers

Cite

M. Cour, M. Simon, L. Argaud, G. Monneret, F. Venet. Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study. Journal of Intensive Care, 2021, 9 (1), pp.64. ⟨10.1186/s40560-021-00580-6⟩. ⟨inserm-03753365⟩
18 View
12 Download

Altmetric

Share

Gmail Facebook X LinkedIn More